Question 1

What is Enhertu?

Accepted Answer

Enhertu is a specialized medication known as an antibody-drug conjugate. It works by combining a monoclonal antibody with a chemotherapy drug to target and destroy cancer cells.

The antibody portion of the medication identifies and attaches to specific proteins on the cell surface, allowing the chemotherapy component to enter and kill the cell directly. This targeted approach is designed to deliver treatment while limiting the impact on healthy cells.

Question 2

What is Enhertu used for?

Accepted Answer

Enhertu is used to treat:

HER2-positive breast cancer

HER2-low breast cancer

HER2-positive gastric cancer

and others.

Question 3

How does Enhertu work?

Accepted Answer

Targeted Delivery System

Enhertu is designed as an antibody-drug conjugate (ADC). This type of medication works by combining a targeted antibody with a potent chemotherapy drug. It specifically targets cells that have a protein called human epidermal growth factor receptor 2 (HER2) on their surface.

How the Medication Works

The process of how Enhertu works in the body involves several steps:

Targeting: The antibody portion of the drug (trastuzumab) circulates through the bloodstream and attaches to HER2 receptors on the surface of cancer cells.

Internalization: Once attached, the cancer cell pulls the entire medication inside itself.

Release: Inside the cell, enzymes break the linker that holds the antibody and chemotherapy together. This releases the chemotherapy drug (deruxtecan) directly into the cell.

Cell Death: The chemotherapy blocks an enzyme called topoisomerase I, which cancer cells need to repair their DNA. This damage prevents the cell from multiplying and eventually causes it to die.

The Bystander Effect

Enhertu is unique because the chemotherapy component can pass through the cell membrane of the initial target cell. This allows it to reach and kill neighboring cancer cells, even if those nearby cells have lower levels of the HER2 protein. This process is often referred to as the bystander effect.

Question 4

What are the active ingredients in Enhertu?

Accepted Answer

The active ingredient in Enhertu is trastuzumab .

Question 5

What are the side effects of Enhertu?

Accepted Answer

Common side effects of Enhertu may include:

Nausea

Fatigue

Vomiting

and others.

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Enhertu?

Accepted Answer

Enhertu belongs to the antibody-drug conjugate drug class.

Question 7

What is the dosage of Enhertu and how do I take it?

Accepted Answer

How Enhertu is Administered

Enhertu is given as an infusion into a vein (intravenous or IV) by a healthcare provider in a clinical setting, such as a hospital or infusion center. It is not a medication you take at home.

Treatment Schedule

This medication is usually given in cycles. A common schedule involves receiving one infusion every three weeks. Your healthcare provider will determine how many cycles of treatment you need based on your condition and how your body responds to the medication.

Infusion Process

The time required for each infusion can vary:

First infusion: The initial dose is typically given slowly over a longer period to monitor for any immediate reactions.

Subsequent infusions: If the first dose is well-tolerated, later infusions may be administered over a shorter period.

Before starting the infusion, your doctor may give you other medications to help prevent side effects like nausea and vomiting.

Missed Doses

If you miss an appointment for an Enhertu infusion, contact your healthcare provider right away to reschedule. It is important to maintain the prescribed timing between doses. Do not wait until your next planned appointment without speaking to your medical team first.

Question 8

Is Enhertu safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Enhertu can cause fetal harm when administered to a pregnant woman. Healthcare providers typically perform a pregnancy test to ensure a patient is not pregnant before starting treatment. If this medication is used during pregnancy, or if a patient becomes pregnant while taking it, there is a risk of serious injury or death to the developing fetus.

Individuals who can become pregnant should use effective contraception during treatment and for at least 7 months after the final dose. Males with female partners of reproductive potential should use effective contraception during treatment and for at least 4 months after the last dose.

Breastfeeding

It is not known whether Enhertu passes into human breast milk. Because of the potential for serious adverse reactions in a nursing child, breastfeeding is not recommended during treatment and for at least 7 months after the final dose.

Fertility

Enhertu may impair fertility in males. Individuals concerned about their ability to have children in the future should discuss these risks with their healthcare provider before starting treatment.

Question 9

What forms and strengths does Enhertu come in?

Accepted Answer

Available Forms

Enhertu is available as a lyophilized powder for injection. It is provided in a single-dose vial and does not contain any preservatives.

Administration

A healthcare provider must reconstitute the powder and dilute it into an infusion bag before it is given to the patient. The medication is administered as an intravenous infusion.

Question 10

What is the FDA approval status of Enhertu?

Accepted Answer

FDA Approval Status

Enhertu (fam-trastuzumab deruxtecan-nxki) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of several advanced or metastatic cancers. It is primarily used for patients who have already received prior treatments. Approved indications include:

Breast Cancer: Used for HER2-positive or HER2-low breast cancer that cannot be removed by surgery or has spread to other parts of the body.

Stomach Cancer: Used for HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Lung Cancer: Used for metastatic non-small cell lung cancer (NSCLC) that carries specific HER2 mutations.

Boxed Warnings

The FDA has required a boxed warning for Enhertu, which is the most serious type of warning for a prescription medication. These warnings cover:

Interstitial Lung Disease (ILD) and Pneumonitis: Enhertu can cause severe, life-threatening, or fatal lung inflammation. Patients must be monitored closely for symptoms such as cough, fever, or shortness of breath. If these symptoms occur, treatment may need to be interrupted or permanently stopped.

Embryo-Fetal Toxicity: This medication can cause significant harm or death to an unborn baby. Healthcare providers require pregnancy testing for females of reproductive potential before starting treatment. Effective birth control must be used during treatment and for a specified period after the final dose.

Administration and Safety Monitoring

Enhertu is administered as an intravenous (IV) infusion by a healthcare professional. Because of its potential for serious side effects, regulatory guidelines require ongoing monitoring of heart function (left ventricular ejection fraction) and respiratory health throughout the course of treatment. It is not recommended for use during pregnancy or while breastfeeding.

Question 11

What should I know about Enhertu and cost?

Accepted Answer

Factors Affecting Price

The total price of Enhertu treatment depends on several variables. Because it is a specialty medication administered in a clinical setting, costs often include more than just the drug itself.

Insurance Coverage: Out-of-pocket costs depend on whether the drug is covered under a medical or pharmacy benefit and the specific terms of the insurance plan.

Treatment Plan: The dosage is calculated based on the patient's weight, and the frequency of infusions affects the overall cost over time.

Clinical Fees: Costs associated with the healthcare facility, nursing staff, and equipment needed for the intravenous infusion are typically billed alongside the medication.

Biosimilar Status

Enhertu is a biologic drug, and there are currently no biosimilar versions available. Biosimilars are similar to generic versions of traditional drugs and often cost less than the original brand-name product.

Financial Support Programs

Financial assistance may be available through the drug manufacturer for patients who meet certain eligibility requirements. These programs can include co-pay assistance for those with commercial insurance or patient assistance programs for individuals without adequate coverage.

Enhertu

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Price Information

FAQ

Additional Resources

Support & Help Resources

Found an Error?